In the Media

CEO of Osmol Therapeutics Leads Virtual Charge to Develop Ground-Breaking Treatment for Prevent Chemo Side-Effects

Bob Linke, CEO of Osmol, was interviewed for the CEO Leadership Series sponsored by Ashton-Tweed, a life sciences executive search firm Mr. Linke discusses OSM-0205, the company’s ground-breaking CIPN treatment and managing a virtual team during the COVID-19 pandemic.

Read at Ashton Tweed

© 2023 Osmol Therapeutics. All rights reserved.

Home          Site Map          Privacy Policy          Terms of Use          Contact

designed and managed by Body1

© 2023 Osmol Therapeutics. All rights reserved.

Home          Site Map          Privacy Policy          Terms of Use          Contact

designed and managed by Body1

© 2023 Osmol Therapeutics. All rights reserved.

Home
Site Map
Privacy Policy
Terms of Use
Contact

designed and managed by Body1

Osmol Therapeutics Initiates IND Enabling Studies to Develop First Therapy for...Osmol Therapeutics Announces Closing of Series A-1 Funding to Advance the Clinical...